Associated Genetic Biomarkers
NCI Definition: A usually painless malignant tumor that arises from adipose tissue. Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes. Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma. The metastatic potential is higher in less differentiated tumors. 
Liposarcomas most frequently harbor alterations in MDM2, CDK4, GLI1, TP53, and TNFAIP3 .
MDM2 Amplification, CDK4 Amplification, GLI1 Amplification, TNFAIP3 Amplification, and TP53 Mutation are the most common alterations in liposarcoma .
Of the biomarker-directed therapies for liposarcoma, 0 are FDA-approved in at least one setting and 1 has NCCN guidelines in at least one setting .
Disease is predicted to be sensitive: -
There are 19 clinical trials for liposarcoma, of which 14 are open and 5 are completed or closed. Of the trials that contain liposarcoma as an inclusion criterion, 5 are phase 1 (3 open), 4 are phase 1/phase 2 (3 open), 9 are phase 2 (7 open), and 1 is phase 3 (1 open).
CDK4, Ganglioside, and MDM2 are the most frequent gene inclusion criteria for liposarcoma clinical trials .
Docetaxel, gemcitabine, and retifanlimab are the most common interventions in liposarcoma clinical trials.
Significant Genes in Liposarcoma
CDK4 is altered in 66.07% of liposarcoma patients .
CDK4 is an inclusion eligibility criterion in 2 clinical trials for liposarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) .
Palbociclib has evidence of efficacy in patients with CDK4 mutation in liposarcoma .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.